Research summaries for 26 peptides — mechanisms, dosing data, and regulatory status.
Body protection compound derived from gastric juice. Studied for tissue repair and gut healing.
Thymosin Beta-4 fragment. Studied for wound healing, angiogenesis, and inflammation reduction.
Copper peptide with studied roles in skin repair, anti-inflammatory activity, and collagen synthesis.
Selective GH secretagogue. Stimulates pituitary GH release with minimal cortisol or prolactin effect.
Modified GHRH analogue with ~30 min half-life. Often combined with a GHRP.
Drug Affinity Complex extends half-life to ~8 days. Once or twice weekly dosing.
GH releasing hexapeptide. Strong GH pulse stimulator with some cortisol and prolactin elevation.
First-generation GHRP. Notable for appetite increase via ghrelin mimicry.
GHRH(1-29) analogue. Previously FDA-approved for GH deficiency diagnosis.
GHRH analogue FDA-approved for HIV-associated lipodystrophy. Also studied for cognitive benefits.
GLP-1 receptor agonist FDA-approved for T2D and obesity (Ozempic, Wegovy). Weekly dosing.
Dual GLP-1/GIP agonist (Mounjaro, Zepbound). FDA-approved for T2D and obesity.
Triple agonist in Phase 3 trials. Shows significant weight loss in clinical research.
C-terminal fragment of hGH. Studied for fat metabolism without IGF-1 or insulin effects.
ACTH(4-7) analogue developed in Russia. Studied for neuroprotection and cognitive enhancement.
Tuftsin analogue with anxiolytic and nootropic properties studied in Russian research.
HGF/SF modulator studied for cognitive enhancement in Alzheimer's models.
Tetrapeptide based on epithalamin. Studied for telomere lengthening and anti-aging effects.
Thymus-derived peptide complex studied for immune modulation and longevity in Russian research.
Approved in 35+ countries for hepatitis B/C and as immunomodulator. Strong research base.
Mitochondria-derived peptide studied for metabolic regulation, insulin sensitivity, and exercise mimicry.
Mitochondria-targeting peptide studied for heart failure and mitochondrial disease. In clinical trials.
Alpha-MSH tripeptide fragment with studied anti-inflammatory and antimicrobial properties.
Oral GH secretagogue. Non-peptide. Increases GH and IGF-1 with once-daily oral dosing.
Melanocortin receptor agonist. FDA-approved for hypoactive sexual desire disorder in women.
Porcine brain-derived peptide mixture studied for neurodegeneration, stroke recovery, and cognition.
For research and educational purposes only. Not medical advice. All information sourced from peer-reviewed literature and publicly available research.